Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker
Alto Neuroscience (NYSE: ANRO) has been granted U.S. Patent Number 12,226,375 for its precision medicine approach in treating Major Depressive Disorder (MDD). The patent covers the use of ALTO-300 (agomelatine) as an adjunctive therapy for patients who have shown inadequate response to antidepressants, specifically using electroencephalogram (EEG) measures for patient selection.
ALTO-300 is an oral, small molecule designed to function as a melatonin agonist and 5-HT2C antagonist. The patent protection extends until 2044, not accounting for potential extensions. The treatment is being developed as an adjunctive therapy for biomarker-characterized MDD patients in the United States who haven't responded adequately to standard antidepressant treatments.
Alto Neuroscience (NYSE: ANRO) ha ricevuto il Brevetto Statunitense Numero 12,226,375 per il suo approccio di medicina di precisione nel trattamento del Disturbo Depressivo Maggiore (MDD). Il brevetto copre l'uso di ALTO-300 (agomelatina) come terapia aggiuntiva per i pazienti che hanno mostrato una risposta inadeguata agli antidepressivi, utilizzando specificamente misure di elettroencefalogramma (EEG) per la selezione dei pazienti.
ALTO-300 è una molecola orale di piccole dimensioni progettata per funzionare come agonista della melatonina e antagonista del 5-HT2C. La protezione brevettuale si estende fino al 2044, senza considerare potenziali estensioni. Il trattamento è in fase di sviluppo come terapia aggiuntiva per pazienti con MDD caratterizzati da biomarcatori negli Stati Uniti che non hanno risposto adeguatamente ai trattamenti antidepressivi standard.
Alto Neuroscience (NYSE: ANRO) ha recibido la Patente de EE. UU. Número 12,226,375 por su enfoque de medicina de precisión en el tratamiento del Trastorno Depresivo Mayor (MDD). La patente cubre el uso de ALTO-300 (agomelatina) como terapia adyuvante para pacientes que han mostrado una respuesta inadecuada a los antidepresivos, utilizando específicamente medidas de electroencefalograma (EEG) para la selección de pacientes.
ALTO-300 es una molécula pequeña oral diseñada para funcionar como agonista de la melatonina y antagonista del 5-HT2C. La protección de la patente se extiende hasta 2044, sin tener en cuenta posibles extensiones. El tratamiento se está desarrollando como terapia adyuvante para pacientes con MDD caracterizados por biomarcadores en los Estados Unidos que no han respondido adecuadamente a los tratamientos antidepresivos estándar.
알토 뉴로사이언스 (NYSE: ANRO)는 주요 우울 장애 (MDD) 치료를 위한 정밀 의학 접근 방식으로 미국 특허 번호 12,226,375를 부여받았습니다. 이 특허는 전기뇌파검사 (EEG) 측정을 사용하여 환자를 선택하는 방식으로, 항우울제에 대한 반응이 불충분한 환자를 위한 보조 요법으로 ALTO-300 (아고멜라틴)의 사용을 포함합니다.
ALTO-300은 멜라토닌 작용제 및 5-HT2C 길항제로 작용하도록 설계된 경구용 소분자입니다. 특허 보호는 2044년까지 유효하며, 잠재적인 연장을 고려하지 않습니다. 이 치료법은 표준 항우울제 치료에 충분히 반응하지 않은 바이오마커 특성화 MDD 환자를 위한 보조 요법으로 미국에서 개발되고 있습니다.
Alto Neuroscience (NYSE: ANRO) a reçu le brevet américain numéro 12,226,375 pour son approche de médecine de précision dans le traitement du trouble dépressif majeur (MDD). Le brevet couvre l'utilisation de ALTO-300 (agomélatine) comme thérapie adjuvante pour les patients ayant montré une réponse insuffisante aux antidépresseurs, en utilisant spécifiquement des mesures d'électroencéphalogramme (EEG) pour la sélection des patients.
ALTO-300 est une petite molécule orale conçue pour agir comme agoniste de la mélatonine et antagoniste du 5-HT2C. La protection par brevet s'étend jusqu'en 2044, sans tenir compte des éventuelles extensions. Ce traitement est en cours de développement comme thérapie adjuvante pour les patients atteints de MDD caractérisés par des biomarqueurs aux États-Unis qui n'ont pas répondu de manière adéquate aux traitements antidépresseurs standards.
Alto Neuroscience (NYSE: ANRO) hat das US-Patent Nummer 12,226,375 für seinen Ansatz der Präzisionsmedizin zur Behandlung der Major Depressive Disorder (MDD) erhalten. Das Patent umfasst die Verwendung von ALTO-300 (Agomelatin) als ergänzende Therapie für Patienten, die unzureichend auf Antidepressiva angesprochen haben, insbesondere unter Verwendung von Elektroenzephalogramm (EEG)-Messungen zur Patientenauswahl.
ALTO-300 ist ein orales, kleines Molekül, das als Melatonin-Agonist und 5-HT2C-Antagonist fungieren soll. Der Patentschutz gilt bis 2044, ohne mögliche Verlängerungen zu berücksichtigen. Die Behandlung wird als ergänzende Therapie für biomarkercharakterisierte MDD-Patienten in den Vereinigten Staaten entwickelt, die nicht ausreichend auf die Standard-Antidepressivum-Behandlungen reagiert haben.
- Patent protection secured until 2044 for ALTO-300 in EEG-defined MDD patient population
- Novel biomarker-based approach potentially improving patient selection efficiency
- Expanding treatment options for patients with inadequate response to current antidepressants
- None.
Insights
The newly granted patent for ALTO-300 represents a significant strategic asset for Alto Neuroscience, with several key implications for investors:
The patent's protection until 2044 provides substantial market exclusivity for ALTO-300's biomarker-guided approach in major depressive disorder. This is particularly valuable in the antidepressant market, where many medications have gone generic. The innovative aspect lies not in the compound itself (agomelatine), but in the precision medicine approach using EEG biomarkers for patient selection.
The commercial potential is noteworthy for several reasons:
- The treatment-resistant depression market represents approximately 30% of MDD patients, creating a substantial addressable market for adjunctive therapies.
- The biomarker-guided approach could significantly improve treatment outcomes by identifying likely responders, potentially commanding premium pricing compared to traditional antidepressants.
- EEG biomarkers provide an objective, measurable basis for patient selection - a rare feature in psychiatry where diagnoses typically rely on subjective assessments.
The patent's scope specifically covering biomarker-guided patient selection creates a strong competitive moat. While competitors might develop similar compounds, the protected EEG-based patient selection method provides a unique market position. This approach aligns with the growing trend toward precision medicine in psychiatry, where treatment selection based on biological markers could significantly improve outcomes and reduce healthcare costs.
However, investors should note that commercial success will depend on several factors:
- Clinical validation of the EEG biomarker's predictive value in identifying responders
- Practical implementation of EEG testing in psychiatric practices
- Payer acceptance of biomarker-guided treatment selection
- Competition from other novel antidepressant approaches, including psychedelics and neurostimulation devices
– Patent supports Alto’s precision approach to improve patient selection –
ALTO-300, also known agomelatine, is an oral, small molecule designed to act as a melatonin agonist and 5-HT2C antagonist and is being developed as an adjunctive treatment in
“The granting of this patent underscores our novel approach to patient selection in neuropsychiatric treatment using objective biomarkers,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. “We are dedicated to developing more effective, targeted treatments for patients with MDD and deepening our understanding of the patient phenotype that is most likely to benefit, based on our unique ALTO-300 biomarker.”
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.
Forward-Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “expects,” “plans,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto’s expectations about the potential benefits, activity, effectiveness and safety of its product candidates and Precision Psychiatry Platform (“Platform”); Alto’s expectations with regard to the design and results of its clinical trials and other statements that are not historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including uncertainties inherent in the progress and completion of clinical trials and clinical development of Alto’s product candidates and other important factors, any of which could cause Alto’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled “Risk Factors” in Alto’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law.
Availability of Information on Alto’s Website
Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219461532/en/
Investor Contact:
Nick Smith
investors@altoneuroscience.com
Media Contact:
Mari Purpura
media@altoneuroscience.com
Source: Alto Neuroscience, Inc.
FAQ
What is the significance of Alto Neuroscience's (ANRO) new patent for ALTO-300?
How does ALTO-300 work in treating Major Depressive Disorder?
What is unique about Alto Neuroscience's (ANRO) approach to MDD treatment?
How long will Alto Neuroscience's patent protection for ALTO-300 last?
